Co-formulation of the RF1V Plague Vaccine with Depot-formulated Cytokines Enhances Immunogenicity and Efficacy to Elicit Protective Responses Against Aerosol Challenge in Mice

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Apr 12

PMID 38605961

Authors

Darrell R Galloway

Jiahui Li

Nguyen X Nguyen

Frank W Falkenberg

Lisa Henning

Robert Krile

Ying-Liang Chou

James N Herron

J Scott Hale

E Diane Williamson

Affiliations

Soon will be listed here.

Abstract

This study evaluated a depot-formulated cytokine-based adjuvant to improve the efficacy of the recombinant F1V (rF1V) plague vaccine and examined the protective response following aerosol challenge in a murine model. The results of this study showed that co-formulation of the Alhydrogel-adsorbed rF1V plague fusion vaccine with the depot-formulated cytokines recombinant human interleukin 2 (rhuIL-2) and/or recombinant murine granulocyte macrophage colony-stimulating factor (rmGM-CSF) significantly enhances immunogenicity and significant protection at lower antigen doses against a lethal aerosol challenge. These results provide additional support for the co-application of the depot-formulated IL-2 and/or GM-CSF cytokines to enhance vaccine efficacy.

Citing Articles

Progress on the research and development of plague vaccines with a call to action.

Williamson E, Kilgore P, Hendrix E, Neil B, Sha J, Chopra A NPJ Vaccines. 2024; 9(1):162.

PMID: 39242587 PMC: 11379892. DOI: 10.1038/s41541-024-00958-1.

Charge Variants Characterization of Co-Formulated Antibodies by Three-Dimensional Liquid Chromatography-Mass Spectrometry.

Jin X, Chen L, Chu J, He B Biomolecules. 2024; 14(8).

PMID: 39199387 PMC: 11352451. DOI: 10.3390/biom14080999.

References

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

HogenEsch H, OHagan D, Fox C . Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018; 3:51. PMC: 6180056. DOI: 10.1038/s41541-018-0089-x. View

Vinuesa C, Linterman M, Yu D, MacLennan I . Follicular Helper T Cells. Annu Rev Immunol. 2016; 34:335-68. DOI: 10.1146/annurev-immunol-041015-055605. View

Moyer T, Kato Y, Abraham W, Chang J, Kulp D, Watson N . Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat Med. 2020; 26(3):430-440. PMC: 7069805. DOI: 10.1038/s41591-020-0753-3. View

Lambrecht B, Kool M, Willart M, Hammad H . Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009; 21(1):23-9. DOI: 10.1016/j.coi.2009.01.004. View

Weber J, Sondak V, Scotland R, Phillip R, Wang F, Rubio V . Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 2002; 97(1):186-200. DOI: 10.1002/cncr.11045. View

Oleszycka E, Lavelle E . Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol. 2014; 28:1-5. DOI: 10.1016/j.coi.2013.12.007. View

Boyman O, Kovar M, Rubinstein M, Surh C, Sprent J . Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006; 311(5769):1924-7. DOI: 10.1126/science.1122927. View

Perry R, Fetherston J . Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev. 1997; 10(1):35-66. PMC: 172914. DOI: 10.1128/CMR.10.1.35. View

10.

Tomala J, Kovar M . IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?. Oncoimmunology. 2016; 5(3):e1102829. PMC: 4839359. DOI: 10.1080/2162402X.2015.1102829. View

11.

Verma S, Tuteja U . Plague Vaccine Development: Current Research and Future Trends. Front Immunol. 2016; 7:602. PMC: 5155008. DOI: 10.3389/fimmu.2016.00602. View

12.

Williamson E, Flick-Smith H, Lebutt C, Rowland C, Jones S, Waters E . Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun. 2005; 73(6):3598-608. PMC: 1111881. DOI: 10.1128/IAI.73.6.3598-3608.2005. View

13.

Sokolovska A, Hem S, HogenEsch H . Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine. 2007; 25(23):4575-85. DOI: 10.1016/j.vaccine.2007.03.045. View

14.

Lawton W, ERDMAN R, SURGALLA M . BIOSYNTHESIS AND PURIFICATION OF V AND W ANTIGEN IN PASTEURELLA PESTIS. J Immunol. 1963; 91:179-84. DOI: 10.21236/ad0299868. View

15.

Kool M, Soullie T, van Nimwegen M, Willart M, Muskens F, Jung S . Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008; 205(4):869-82. PMC: 2292225. DOI: 10.1084/jem.20071087. View

16.

Hutchison S, Benson R, Gibson V, Pollock A, Garside P, Brewer J . Antigen depot is not required for alum adjuvanticity. FASEB J. 2011; 26(3):1272-9. PMC: 3289510. DOI: 10.1096/fj.11-184556. View

17.

Gracio A, Gracio M . Plague: A Millenary Infectious Disease Reemerging in the XXI Century. Biomed Res Int. 2017; 2017:5696542. PMC: 5585619. DOI: 10.1155/2017/5696542. View

18.

Nunberg J, Doyle M, York S, YORK C . Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci U S A. 1989; 86(11):4240-3. PMC: 287426. DOI: 10.1073/pnas.86.11.4240. View

19.

Somani J, Lonial S, Rosenthal H, Resnick S, Kakhniashvili I, Waller E . A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses. Vaccine. 2002; 21(3-4):221-30. DOI: 10.1016/s0264-410x(02)00463-2. View

20.

Assen F, Sixt M . The Dynamic Cytokine Niche. Immunity. 2017; 46(4):519-520. DOI: 10.1016/j.immuni.2017.04.006. View